Northwestern Mutual Wealth Management Co. Grows Stock Holdings in Illumina, Inc. $ILMN

Northwestern Mutual Wealth Management Co. grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 2,440.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,397 shares of the life sciences company’s stock after acquiring an additional 38,807 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Illumina were worth $5,298,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ILMN. JPMorgan Chase & Co. lifted its stake in shares of Illumina by 17.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock valued at $79,081,000 after purchasing an additional 124,246 shares during the period. Elo Mutual Pension Insurance Co acquired a new position in shares of Illumina in the 3rd quarter valued at $2,319,000. Caprock Group LLC acquired a new position in shares of Illumina in the 3rd quarter valued at $1,479,000. Rakuten Investment Management Inc. acquired a new position in shares of Illumina in the 3rd quarter valued at $861,000. Finally, Capital World Investors lifted its stake in shares of Illumina by 20.0% in the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after purchasing an additional 3,331,542 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Performance

NASDAQ:ILMN opened at $144.41 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The company has a fifty day moving average of $130.45 and a two-hundred day moving average of $130.91. The stock has a market capitalization of $21.85 billion, a PE ratio of 26.26, a P/E/G ratio of 2.39 and a beta of 1.42. Illumina, Inc. has a fifty-two week low of $78.55 and a fifty-two week high of $155.53.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, research analysts forecast that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of several analyst reports. Royal Bank Of Canada initiated coverage on shares of Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 target price for the company. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Thursday, May 14th. Barclays boosted their target price on shares of Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research note on Friday, May 1st. JPMorgan Chase & Co. boosted their target price on shares of Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Finally, Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Seven research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $137.75.

Insiders Place Their Bets

In other Illumina news, Director Keith A. Meister sold 225,067 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $145.55, for a total transaction of $32,758,501.85. Following the completion of the transaction, the director directly owned 3,604,441 shares in the company, valued at approximately $524,626,387.55. This represents a 5.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the transaction, the senior vice president owned 15,056 shares of the company’s stock, valued at $2,093,386.24. This represents a 4.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 330,160 shares of company stock valued at $48,028,308 over the last 90 days. 2.90% of the stock is currently owned by company insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.